Finoriq research workspace
Caris Life Sciences, Inc. (CAI) SEC Filings & Filing Highlights
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular. Review CAI SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
- Company
- Caris Life Sciences, Inc. (CAI)
- Ticker
- CAI
- Market Cap
- $4.4B
- Latest Price
- $15.58
- Industry
- Medical Devices
Caris Life Sciences, Inc. (CAI) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Caris Life Sciences, Inc. (CAI).
| Event | Form | Date |
|---|---|---|
| The shareholder voting results by proposal are set forth in the tables belowCaris Life Sciences, Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders on June 4, 2026 (the “2026 Annual Meeting”). The Com... | 8-K5.07 | 2026-06-05 |
| Caris Life Sciences Reports First Quarter 2026 Financial ResultsCaris Life Sciences Reports First Quarter 2026 Financial Results | 8-K2.02 | 2026-05-07 |
| Caris Life Sciences, Inc.: Agreement terminationOn the Closing Date, the Company used proceeds under the Initial Term Facility to repay all outstanding indebtedness under that certain cre... | 8-K1.02 | 2026-04-02 |
| The Delayed Draw Facility may be used by the Company and its subsidiaries solely in connection...On April 1, 2026 (the “Closing Date”), Caris Life Sciences, Inc., a Texas corporation (the “Company”) entered into a Financing Agreement, d... | 8-K1.01 | 2026-04-02 |
| Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 20...Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook | 8-K7.01 | 2026-02-26 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.